Seres Therapeutics, Inc.
MCRBDrugs in Pipeline
1
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Aug 5, 2026
7dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
MCRB Earnings Report
EPS Est: $-2.07 | FQ end 2026-06
How MCRB's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
SER-109 | Phase 3 | Clostridium Difficile Infection | - | - |
Clostridium Difficile Infection
1 drug in this indication
Clostridium Difficile
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Seres Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Seres Therapeutics, Inc.'s (MCRB) pipeline across Phase 3. Its lead program is SER-109 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Seres Therapeutics, Inc.'s next FDA catalyst?→
Seres Therapeutics, Inc.'s (MCRB) next tracked catalyst is a Earnings expected August 5, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track MCRB biotech catalysts?→
Add MCRB to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Seres Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.